AstraZeneca's Indian COVID-19 vaccine partner told to prioritize local supplies: CEO

Low- and middle-income countries banking on doses of AstraZeneca’s COVID-19 vaccine from Serum Institute of India may have to wait a bit longer, the Indian shot maker’s CEO said over the weekend. The same goes for Europe, where officials have reportedly considered importing supplies from the world's largest vaccine maker by doses. Serum Institute has been told to prioritize supplies for India first as the country hustles to vaccinate 300 million people, or a fifth of its population, by August. The move could signal delays for other countries waiting on orders of AstraZeneca’s adenovirus shot, which Serum Institute is cranking out on license under the name Covishield.